Detailed Information on Publication Record
2022
Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care
MAZURAKOVA, Alena, Lenka KOKLESOVA, Marek SAMEC, Erik KUDELA, Karol KAJO et. al.Basic information
Original name
Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care
Authors
MAZURAKOVA, Alena, Lenka KOKLESOVA, Marek SAMEC, Erik KUDELA, Karol KAJO, Veronika SKUCIOVA, Sandra Hurta CSIZMAR, Veronika MESTANOVA, Martin PEC, Marian ADAMKOV, Raghad Khalid AL-ISHAQ, Karel ŠMEJKAL (203 Czech Republic, belonging to the institution), Frank A GIORDANO, Dietrich BUSSELBERG, Kamil BIRINGER, Olga GOLUBNITSCHAJA and Peter KUBATKA
Edition
EPMA JOURNAL, Cham, SPRINGER INT PUBL AG, 2022, 1878-5077
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30104 Pharmacology and pharmacy
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 6.500
RIV identification code
RIV/00216224:14160/22:00129768
Organization unit
Faculty of Pharmacy
UT WoS
000782529800001
Keywords in English
Breast cancer; Phytochemicals; Individualized patient profiling; Modifiable risk factors; Health risk assessment; Molecular patterns; Predictive Preventive Personalized Medicine (PPPM/3PM); Primary secondary tertiary care; Treated cancer; COVID-19
Tags
International impact, Reviewed
Změněno: 20/4/2023 17:05, JUDr. Sabina Krejčiříková
Abstract
V originále
Breast cancer incidence is actually the highest one among all cancers. Overall breast cancer management is associated with challenges considering risk assessment and predictive diagnostics, targeted prevention of metastatic disease, appropriate treatment options, and cost-effectiveness of approaches applied. Accumulated research evidence indicates promising anti-cancer effects of phytochemicals protecting cells against malignant transformation, inhibiting carcinogenesis and metastatic spread, supporting immune system and increasing effectiveness of conventional anti-cancer therapies, among others. Molecular and sub-/cellular mechanisms are highly complex affecting several pathways considered potent targets for advanced diagnostics and cost-effective treatments. Demonstrated anti-cancer affects, therefore, are clinically relevant for improving individual outcomes and might be applicable to the primary (protection against initial cancer development), secondary (protection against potential metastatic disease development), and tertiary (towards cascading complications) care. However, a detailed data analysis is essential to adapt treatment algorithms to individuals’ and patients’ needs. Consequently, advanced concepts of patient stratification, predictive diagnostics, targeted prevention, and treatments tailored to the individualized patient profile are instrumental for the cost-effective application of natural anti-cancer substances to improve overall breast cancer management benefiting affected individuals and the society at large.